First Trust NYSE Arca Biotechnology Index Fund (FBT)

134.65
Delayed Data
As of Apr 23
 +0.05 / +0.04%
Today’s Change
102.93
Today|||52-Week Range
147.10
+8.09%
Year-to-Date

Investment Objective

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.

No recent news for First Trust NYSE Arca Biotechnology Index Fund.

Performance

1 month+1.60% 3 years+3.26%
3 months-6.06% 5 years+18.60%
1 year+31.01% Since inception+17.60%
Data through 04/24/2018

Quote Details

Previous close$134.60
Open day’s range134.10 – 135.86
Net asset value (NAV)134.65 (04/23/2018)
Daily volume41,714
Average volume (3 months)68,540
Data as of 8:00pm ET, 04/23/2018

Peer Comparisonvs. Health ETFs

 FBTCategory
Performance 5-yr return+18.60%+14.29%
Expense Gross exp ratio0.56%1.30%
Risk 5 year sharpe ratio0.860.92
Net assets$1.4B$3.0B
Average market cap$10.8B$10.0B
Average P/E--22.2
Dividend / Share--0.30%

Competitors

XLV Health Care Select Sector SPDR® Fund
FHLC Fidelity® MSCI Health Care Index ETF
VHT Vanguard Health Care Index Fund ETF Shar...

Holdings

Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
AVXS AveXis Inc5.04%
NKTR Nektar Therapeutics4.95%
XON Intrexon Corp3.94%
AGIO Agios Pharmaceuticals Inc3.91%
TECH Bio-Techne Corp3.58%
ICPT Intercept Pharmaceuticals Inc3.56%
RARE Ultragenyx Pharmaceutical Inc3.46%
VRTX Vertex Pharmaceuticals Inc3.44%
NBIX Neurocrine Biosciences Inc3.43%
ALKS Alkermes Plc3.39%